7,000 Shares in Tempus AI, Inc. (NASDAQ:TEM) Acquired by James J. Burns & Company LLC

James J. Burns & Company LLC acquired a new stake in Tempus AI, Inc. (NASDAQ:TEM) during the 4th quarter, according to the company in its most recent filing with the SEC. The institutional investor acquired 7,000 shares of the company’s stock, valued at approximately $236,000.

A number of other hedge funds and other institutional investors also recently added to or reduced their stakes in the stock. First Horizon Advisors Inc. bought a new stake in Tempus AI during the 3rd quarter valued at approximately $30,000. FNY Investment Advisers LLC acquired a new position in shares of Tempus AI in the fourth quarter valued at $67,000. Vestor Capital LLC bought a new position in Tempus AI during the third quarter worth about $153,000. Stifel Financial Corp acquired a new stake in Tempus AI in the 3rd quarter valued at $218,000. Finally, IQ EQ FUND MANAGEMENT IRELAND Ltd bought a new stake in Tempus AI in the third quarter valued at $258,000. Hedge funds and other institutional investors own 24.22% of the company’s stock.

Tempus AI Price Performance

NASDAQ TEM opened at $61.54 on Tuesday. The company has a debt-to-equity ratio of 8.17, a quick ratio of 2.55 and a current ratio of 2.69. Tempus AI, Inc. has a fifty-two week low of $22.89 and a fifty-two week high of $79.49. The business has a fifty day moving average price of $44.14 and a two-hundred day moving average price of $48.44.

Insiders Place Their Bets

In related news, CEO Eric P. Lefkofsky sold 82,056 shares of the business’s stock in a transaction on Friday, January 31st. The shares were sold at an average price of $58.21, for a total value of $4,776,479.76. Following the transaction, the chief executive officer now owns 5,532,987 shares in the company, valued at $322,075,173.27. The trade was a 1.46 % decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at this hyperlink. Also, major shareholder Bradley A. Keywell sold 395,800 shares of the firm’s stock in a transaction that occurred on Wednesday, December 11th. The stock was sold at an average price of $42.95, for a total value of $16,999,610.00. Following the sale, the insider now directly owns 16,164,449 shares of the company’s stock, valued at $694,263,084.55. This represents a 2.39 % decrease in their position. The disclosure for this sale can be found here. Insiders have sold 2,037,702 shares of company stock valued at $89,449,651 in the last ninety days.

Analyst Ratings Changes

A number of equities analysts have weighed in on the stock. Loop Capital dropped their target price on shares of Tempus AI from $57.00 to $52.00 and set a “buy” rating for the company in a research note on Tuesday, January 14th. Guggenheim initiated coverage on Tempus AI in a research report on Monday, December 9th. They issued a “buy” rating and a $74.00 price objective for the company. Bank of America raised their target price on shares of Tempus AI from $52.00 to $54.00 and gave the company a “neutral” rating in a research note on Friday, December 13th. Needham & Company LLC reiterated a “buy” rating and issued a $56.00 price objective on shares of Tempus AI in a report on Tuesday, January 14th. Finally, Piper Sandler restated a “neutral” rating and issued a $70.00 price objective (up previously from $40.00) on shares of Tempus AI in a research report on Tuesday, November 12th. Three investment analysts have rated the stock with a hold rating and nine have issued a buy rating to the company’s stock. According to data from MarketBeat.com, Tempus AI currently has an average rating of “Moderate Buy” and a consensus price target of $56.36.

About Tempus AI

Tempus AI Inc is a technology company advancing precision medicine through the practical application of artificial intelligence principally in healthcare. The company provides AI-enabled precision medicine solutions to physicians to deliver personalized patient care and in parallel facilitates discovery, development and delivery of optimal therapeutics.